

JAN 13 2003

Sheet 1 of 4Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
06666-149001Application No.  
09/997,525**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Erlinda M. Gordon et al.Filing Date  
November 29, 2001

Group Art Unit

~~1646~~1632**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
RR9	AA	6,004,798	Dec 21, 1999	Anderson et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

JAN 15 2003

TECH CENTER 1600/2900

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
RR9	AR	Asher, et al., "Murine Tumor Cells Transduced with the Gene for Tumor Necrosis Factor- $\alpha$ ", <u>The Journal of Immunology</u> , Vol. 146, No. 9, pp. 3227-3234, May 1, 1991
	AR	Blankenstein, et al., "Tumor Suppression after Tumor Cell-targeted Tumor Necrosis Factor $\alpha$ Gene Transfer", <u>The Journal of Experimental Medicine</u> , Vol. 173, No. 5, pp. 1047-1052, May, 1991
RR9	AS	Borrello, et al., "A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccines", <u>Human Gene Therapy</u> , Vol. 10, No. 12, pp. 1983-1991, August 10, 1999


Examiner Signature

RR9

Date Considered

8/8/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
06666-149001Application No.  
09/997,525**RECEIVED****Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant

Erlinda M. Gordon et al.

JAN 15 2003

Filing Date

November 29, 2001

Group Art Unit

1646/6 TECH CENTER 1600/2900

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
RCS	<del>AT</del>	Coze, et al., "characteristics and Immunomodulatory Properties of Human Neuroblastoma Cells after Retrovirus-Mediated Gene Transfer of the Cytokine Genes IL-2 and IFN- $\gamma$ ", <u>Transgenics</u> , Vol. 1, No. 6, pp. 585-595, 1995
	<del>AU</del>	Dranoff, et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity", <u>Proceedings of the National Academy of Sciences</u> , Vol. 90, No. 8, pp. 3539-3543, April 15, 1993
	<del>AV</del>	Fearon, et al., "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response", <u>Cell</u> , Vol 60, No. 3, pp. 397-403, February 9, 1990
	<del>AW</del>	Fong, et al., "The Use and Development of Retroviral Vectors to Deliver Cytokine Genes for Cancer Therapy", <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> , Vol. 17, No. 1, pp. 1-60, 2000
	<del>AX</del>	Foreman, et al., "Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication", <u>British Journal of Cancer</u> , Vol. 67, pp. 933-938, 1993
	<del>AY</del>	Gansbacher, et al., "Retroviral lymphokine gene transfer induced secretion of Interleukin-2 (IL-2) or Interferon-gamma (IFN- $\gamma$ ) by human melanoma cells", Eighty-Second annual meeting of the American Association for Cancer Research Proceedings, Houston, Texas, Vol 32, 1514 (Abstract) May 15-18, 1991
	<del>AZ</del>	Gilboa, "Immunotherapy of Cancer with Genetically Modified Tumor Vaccines", <u>Seminars in Oncology</u> , Vol. 23, No. 1, pp. 101-107, February, 1996
	<del>AAA</del>	Golumbek, "Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4", <u>Science</u> , Vol. 254, pp. 713-716, 1 November 1991
	<del>ABB</del>	Gordon, et al., "Inhibition of Metastatic Tumor Growth in Nude Mice by Portal Vein Infusions of Matrix-targeted Retroviral Vectors Bearing a Cytocidal Cyclin G1 Construct", <u>Cancer Research</u> , Vol. 60, No. 13, pp. 3343-3347, July 1, 2000
	<del>ACC</del>	Gordon, et al., "Systemic Administration of a Matrix-Targeted Retroviral Vector is Efficacious for Cancer Gene Therapy in Mice", <u>Human Gene Therapy</u> , Vol. 12, No. 2, pp. 193-204, January 20, 2001
	<del>ADD</del>	Guinan, et al., "Pivotal Role of the B7:CD28 Pathway in Transplantation Tolerance and Tumor Immunity", <u>Blood</u> , Vol. 84, No. 10., pp. 3261-3282, November 15, 1994
	<del>ABE</del>	Hall, et al., "Molecular Engineering of Matrix-Targeted Retroviral Vectors Incorporating a Surveillance Function Inherent in von Willebrand Factor", <u>Human Gene Therapy</u> , Vol 22. No. 7, pp. 983-993, May 1, 2000
	<del>APF</del>	Handgretinger et al., "Interferon-Gamma Upregulates the Susceptibility of Human Neuroblastoma Cells to Interleukin-2-Activated Natural Killer Cells", <u>Natural Immunity and Cell Growth Regulation</u> , Vol. 8, pp. 189-196, July/August 1989
	<del>AGG</del>	Hock, et al., "Interleukin 7 Induces CD4 <sup>+</sup> T Cell-dependent Tumor Rejection", <u>The Journal of Experimental Medicine</u> , Vol. 174, No. 6, pp. 1291-1298, December 1, 1991
	<del>AHH</del>	Jaffee, "Immunotherapy of Cancer", <u>Annals of The New York Academy of Sciences</u> , Vol. 886, pp. 67-72
RCS	<del>AH</del>	Kim, et al., "Macrophage Colony-Stimulating Factor Can Modulate Immune Responses and Attract Dendritic Cells <i>in Vivo</i> ", <u>Human Gene Therapy</u> , Vol. 11, No. 2, pp. 305-321, January 20, 2000


Examiner Signature

RCS

Date Considered

8/8/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
JAN 15 2003  
TECH CENTER 1600/2906

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06666-149001	Application No. 09/997,525
Information Disclosure Statement by Applicant (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Erlinda M. Gordon et al.	
		Filing Date November 29, 2001	Group Art Unit 1646/1632

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
RMS	<del>AJJ</del>	Knobloch, et al., "T cell receptor diversity in severe combined immunodeficiency following HLA-haploidentical bone marrow transplantation", <u>Bone Marrow Transplantation</u> , Vol. 8, No. 5, pp. 383-387, November, 1991
	<del>AKK</del>	Kurane, et al., "Cytokines as an Adjuvant to Tumor Vaccines: Efficacy of Local Methods of Delivery", <u>Annals of Surgical Oncology</u> , Vol. 4, No. 7, pp. 579-585, 1997
	<del>ALL</del>	Liu, et al., "Incorporation of Tumor Vasculature Targeting Motifs into Moloney Murine Leukemia Virus Env Escort Proteins Enhances Retrovirus Binding and Transduction of Human Endothelial Cells", <u>Journal of Virology</u> , Vol. 74, No. 11, pp. 5320-5328, 2000
	<del>AMM</del>	Mackensen, et al., "Immunostimulatory Cytokines in Somatic Cells and Gene Therapy of Cancer", <u>Cytokine and Growth Factor Reviews</u> , Vol. 8, No. 2, pp. 119-128, June, 1997
	<del>ANN</del>	Main, et al., "Human Neuroblastoma Cell Lines are Susceptible to Lysis by Natural Killer Cells But Not by Cytotoxic T Lymphocytes", <u>The Journal of Immunology</u> , Vol. 135, No. 1, pp. 242-246, July, 1985
	<del>AOO</del>	Mellstedt, et al., "Augmentation of the Immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors", <u>Current Opinion in Hematology</u> , Vol. 6, pp. 169-175, 1999
	<del>APP</del>	Mendiratta, et al., "Combination of Interleukin 12 and interferon $\alpha$ Gene therapy Induces a Synergistic Antitumor Response against Colon and Renal Cell Carcinoma", <u>Human Gene Therapy</u> , Vol. 11, No. 13, pp. 1851-1862, September 1, 2000
	<del>AQQ</del>	Miller, et al., "Intratumoral Administration of Adenoviral Interleukin 7 Gene-Modified Dendritic Cells Augments Specific Antitumor Immunity and Achieves Tumor Eradication", <u>Human Gene Therapy</u> , Vol. 11, No. 1, pp. 53-65, January 1, 2000
	<del>ARR</del>	Morgan, et al., "Analysis of the Functional and Host Range-Determining Regions of the Murine Ecotropic and Amphotropic Retrovirus Envelope Proteins", <u>Journal of Virology</u> , Vol. 67, No. 8, pp. 4712-4721, August, 1993
	<del>ASS</del>	Nabel, et al., "Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans", <u>Proceedings of the National Academy of Sciences</u> , Vol. 90, No. 23, pp. 11307-11311, December 1, 1993
	<del>ATT</del>	Nagai, et al., "Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice", <u>Cancer Immunology Immunotherapy</u> , Vol. 47, pp. 72-80, 1998
	<del>ALU</del>	Skotzko, et al., "Retroviral Vector-mediated Gene Transfer of Antisense Cyclin G1 (CYCG1) Inhibits Proliferation of Human Osteogenic Sarcoma Cells", <u>Cancer Research</u> , Vol. 55, No. 23, pp. 5493-5498, December 1, 1995
	<del>AVV</del>	Soneoka, et al., "A transient three-plasmid expression system for the production of high titer retroviral vectors", <u>Nucleic Acids Research</u> , Vol. 23, No. 4, pp. 628-633, February 25, 1995
<del>AWW</del>	Suh, et al., "Treatment of Liver Metastases from Colon Carcinoma with Autologous Tumor Vaccine Expressing Granulocyte-Macrophage Colony-stimulating Factor", <u>Journal of Surgical Oncology</u> , Vol. 72, No. 4, pp. 218-224, December, 1999	
<del>AXX</del>	Tepper, et al., "Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells", <u>Human Gene Therapy</u> , Vol. 5, No. 2, pp. 153-164, February, 1994	
RMS	<del>AYY</del>	Ucar, et al., "Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector", <u>Cancer Gene Therapy</u> , Vol. 2, No. 3, pp. 171-181, 1995


Examiner Signature

RMS

Date Considered

8/8/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>Substitute Form PTO-1449</b> (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	<b>U.S. Department of Commerce Patent and Trademark Office</b>	<b>Attorney's Docket No.</b> 06666-149001	<b>Application No.</b> 09/997,525
	<b>Applicant</b> Erlinda M. Gordon et al.		
	<b>Filing Date</b> November 29, 2001	<b>Group Art Unit</b> <del>1646</del> 1632	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
<b>Examiner Initial</b>	<b>Desig. ID</b>	<b>Document</b>
RMS	<del>AZZ</del>	Warren, et al., "Uses of granulocyte-macrophage colony-stimulating factor in vaccine development", <u>Current Opinion in Hematology</u> , Vol. 7, pp. 168-173, 2000
RMS	<del>AAAA</del>	Watanabe, et al., "Exogenous expression of mouse interferon $\gamma$ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity", <u>Proceedings of the National Academy of Sciences</u> , Vol. 86, No. 23, pp. 9456-9459, December, 1989

<b>Examiner Signature</b> RMS	<b>Date Considered</b> 8/8/03
<b>EXAMINER:</b> Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	